How do oligodendrocytes initiate neuroinflammation in PD when microglia are traditionally considered primary drivers?

Mechanistic Hypotheses: Oligodendrocyte-Driven Neuroinflammation in PD

Hypothesis 1: PSAP Cleavage Pattern Determines Pro-inflammatory vs. Protective Function

Title: Altered Prosaposin Processing Drives Neurotoxicity

Mechanism: Prosaposin (PSAP) is proteolytically cleaved into four saposins (Sap-A, -B, -C, -D) with distinct biological functions. We hypothesize that in PD, dysregulated cleavage (possibly by cathepsins or MMPs) generates a pathogenic cleavage pattern enriched in specific saposin fragments that disproportionately activate the PSAP-GPR37-IL-6 axis. The uncleaved propeptide may normally function as a reservoir with anti-inflammatory properties, while disease-associated proteases shunt processing toward neurotoxic fragments.

Key Evidence: Cathepsin D (CTSD) activity is increased in PD substantia nigra (PMID: 31722267), and CTSD can cleave PSAP. Altered saposin ratios have been implicated in Gaucher disease and related synucleinopathies (PMID: 29104288).

Testable Prediction: Mass spectrometry quantification of individual saposin fragments in post-mortem PD vs. age-matched control substantia nigra tissue will reveal a disease-specific cleavage signature; siRNA knockdown of candidate proteases (CTSD, MMP-2/9) in oligodendrocytes will normalize the cleavage pattern and reduce IL-6 secretion in vitro.

Target Gene/Protein: Prosaposin (PSAP)

Critical Evaluation: Hypothesis 1 — PSAP Cleavage Pattern

Summary of Hypothesis

1. Specific Weakness

The cell-type specificity of the proposed axis is underexplained — GPR37 is expressed broadly, yet the mechanism is claimed as oligodendrocyte-unique.

PSAP is a ubiquitously expressed lysosomal protein critical for glycosphingolipid catabolism across all cell types. If disease-associated proteases (e.g., elevated CTSD) alter cleavage globally, why does this selectively drive pathology via oligodendrocyte GPR37 signaling? GPR37 and GPR37L1 are expressed in neurons, astrocytes, and microglia as well. The source paper must address whether oligodendrocytes have: (a) uniquely high basal PSAP expression or storage, (b) preferential access to extracellular PSAP release, or (c) uniquely responsive GPR37 coupling to IL-6 transcription vs. other cell types. Without this, the mechanism reads as oligodendrocyte-attributed but mechanistically cell-type-neutral.

Supporting concern: GPR37 knockout mice show no overt neurodevelopmental phenotype (PMID: 15845801), and GPR37L1 null mice exhibit only subtle cerebellar defects (PMID: 19587354), suggesting compensatory mechanisms or context-dependent signaling that the hypothesis does not address.

2. Counter-Evidence and Known Complications

A. IL-6 as a downstream effector of GPR37 in oligodendrocytes is not mechanistically established.
The GPR37 literature describes ligand-dependent coupling to Gαs (cAMP), Gαi, and β-arrestin pathways. While GPR37 activation can theoretically influence NF-κB or STAT3 signaling, the specific coupling to IL-6 transcription in oligodendrocytes is not a canonical pathway. IL-6 is prominently produced by microglia and astrocytes in PD models (PMID: 32386210). The assumption that oligodendrocyte-derived IL-6 is the primary neuroinflammatory signal requires direct biochemical evidence (e.g., GPR37 Gαs activation → PKA → unidentified transcription factor → IL-6) that is likely missing.

B. Elevated cathepsin D in PD substantia nigra may be secondary, not causal.
The cited PMID 31722267 reports increased CTSD activity in PD SN, but this observation could represent a compensatory autophagy response to accumulated α-synuclein or a consequence of oxidative stress — both well-documented features of PD pathogenesis. Establishing CTSD elevation as a cause of altered PSAP cleavage (rather than an epiphenomenon) requires temporal evidence: does CTSD upregulation precede measurable IL-6 increases and neurodegeneration?

C. PSAP cleavage is tightly regulated by multiple proteases — single-protease models are insufficient.
Prosaposin processing involves at minimum furin, cathepsins, and possibly aspartic protease D in a sequential, compartment-specific manner (endosomal → lysosomal). The hypothesis proposes siRNA against "candidate proteases" broadly, but validating which specific protease(s) generate the "pathogenic cleavage pattern" in PD oligodendrocytes is non-trivial. Off-target effects of cathepsin inhibition are substantial given cathepsins' broad substrate specificity. Moreover, compensatory upregulation of redundant proteases could mask the effect.

3. Pointed Question

If PSAP cleavage is globally altered in PD (as suggested by CTSD elevation across cell types), what prevents neurons, astrocytes, and microglia from also exhibiting overactivated GPR37-IL-6 signaling — and what specific feature of oligodendrocyte biology makes them the "drivers" rather than passive responders?

The source paper must establish: (a) oligodendrocyte-restricted or -enriched processing of the pathogenic cleavage pattern, (b) cell-type-specific GPR37 expression/function, or (c) a permissive signaling environment unique to oligodendrocytes that translates PSAP fragments into IL-6 production. Absent this, the cell-type attribution is a label attached to a cell-type-general mechanism.

4. Confidence Rating

Moderate

Justification: The hypothesis is mechanistically coherent and builds on established biology (PSAP cleavage, CTSD elevation in PD, GPR37 as a signaling receptor). The link to oligodendrocytes is plausible but under-argued — the Cell Rep paper presumably provides primary evidence, but the specific weakness identified here (loss of cell-type specificity) is a significant vulnerability if not addressed. The therapeutic prediction is testable but requires substantial validation of the upstream cleavage event before it can be considered actionable. Strengthen by demonstrating oligodendrocyte-selective features of the axis; weaken by noting that GPR37 biology is complex and not exclusively pro-inflammatory. Summary for Theorist: The PSAP cleavage hypothesis is

Domain Expert Response: PD Translational Assessment

Preliminary Note: AD vs. PD Context

I notice the query references an "Alzheimer's clinical landscape," but the research question, source paper, and mechanistic hypotheses all concern Parkinson's disease. I will evaluate these hypotheses within the PD translational context, as that aligns with the source material.

Question 1: Hypotheses with Highest Translational Potential

Hypothesis 1 (PSAP Cleavage Pattern) — Highest Potential

This hypothesis identifies a druggable upstream node in a disease-relevant pathway. The appeal lies in targeting protease activity or PSAP processing rather than downstream inflammatory effectors, potentially achieving disease modification rather than symptomatic anti-inflammation.

Hypothesis 2 (Undisclosed in Prompt) — Assuming Standard Secondary Hypotheses

A GPR37 antagonism/inverse agonism approach would leverage an existing receptor target with known pharmacology. GPR37 is a GPCR (class A), which offers well-established drug discovery infrastructure. Small-molecule GPR37 modulators exist (e.g., compounds from Parkinson's-associated neuroprotection screens), though none are clinically advanced.

Hypothesis 3 — IL-6 Axis Blockade as Adjunct

Repurposing tocilizumab or sarilumab (anti-IL-6R antibodies) for PD has moderate translational potential given:

• Established safety profiles (RA, giant cell arteritis)
• Ongoing trials in other neurodegenerative contexts
• Clear biomarker pathway (IL-6, CRP as pharmacodynamic markers)

Question 2: Clinical Evidence, Safety, and Patient Population

Anti-IL-6R Approaches (Tocilizumab/Sarilumab)

| Dimension | Assessment |
|-----------|------------|
| Current Evidence | No completed Phase II/III PD trials as of my knowledge cutoff. Early-phase studies exploring neuroinflammatory biomarkers. Limited but growing evidence from ALS and AD trials. |
| Safety | Well-characterized. Key concerns: immunosuppression (infection risk), hepatotoxicity, cytopenias. PD population is typically older with comorbidities—risk-benefit profile requires careful patient selection. |
| Patient Population Fit | Best suited for patients with evidence of active neuroinflammation (elevated CSF IL-6, TSPO-PET positivity). Not appropriate for all PD patients; requires biomarker stratification. |

GPR37-Targeting Approaches

| Dimension | Assessment |
|-----------|------------|
| Current Evidence | Preclinical only. GPR37 ligandands are poorly characterized; the receptor's "orphan" status was only recently resolved. |
| Safety | Unknown